Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Nicoletta Colombo, Cristiana Sessa, Andreas du Bois et al. · Annals of Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pathology +17

Folate receptor alpha as a tumor target in epithelial ovarian cancer

Kimberly R. Kalli, Ann L. Oberg, Gary L. Keeney et al. · Gynecologic Oncology · 2008 · 467 citations · Full text

Medicine, Cancer Biology, Oncology +11

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny et al. · New England Journal of Medicine · 2023 · 414 citations · Full text

Medicine, Oncology, Pharmacology +16

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 405 citations · Full text

Medicine, Gynecology, Oncology +13